The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
MURANO: Final analysis and substudy results of VenR in R/R CLL
|
High-level expression of the antiapoptotic protein BCL2 is a key feature of CLL, making it an ideal therapeutic target.1 The phase III MURANO trial (NCT02005471) evaluated the efficacy of venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) in patients R/R CLL.1,2 Patients were randomly assigned to receive VenR (n = 194) or BR (n = 195).1 The primary endpoint was investigator-assessed PFS, with MRD status a key secondary endpoint.1 In the substudy, patients with PD received VenR as retreatment (n = 25) or crossover from BR (n = 9) and patient outcomes were analyzed based on patient’s genetic profiles.2 Results were published by Kater et al. in Blood.2 |
| Key learnings |
| The mPFS was significantly higher for VenR vs BR at 54.7 months vs 17 months, respectively (p < 0.0001). The 7-year PFS rate was 23% for VenR, with no BR-treated patients remaining progression-free at this time.1 |
| For VenR-treated patients with uMRD/no PD at EOT, the mPFS was 52.5 months, vs 18.0 months for those with MRD at EOT (p < 0.0001).1 |
| The substudy results showed encouraging outcomes with VenR-retreated and VenR-crossover patients; mPFS was 23 months and 27 months, and best ORR was 72% and 89%, respectively.2 |
| The results of the MURANO trial demonstrate long-term deep and durable efficacy for VenR. The data provide continued support for the treatment of R/R CLL with fixed-duration VenR, and suggest that VenR retreatment is a viable option.1 |
Abbreviations: BR, bendamustine-rituximab; CLL, chronic lymphocytic leukemia; EOT, end of treatment; mPFS, median progression-free survival; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PD, progressive disease; R/R, relapsed/refractory; uMRD, undetectable MRD; VenR, venetoclax-rituximab.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
